Director Grant C. Bogle of Immuneering Corp filed a Form 4 on November 9, 2026, disclosing the acquisition of stock options covering 66,700 shares of Class A Common Stock at an exercise price of $3.65 per share.

Key Highlights

  • Reporting person: Grant C. Bogle, identified as a Director of Immuneering Corp (NASDAQ:IMRX).
  • Transaction date: November 9, 2026, with transaction code "A" (acquired).
  • Options granted: 66,700 stock options at an exercise price of $3.65 per share.
  • Price of derivative security: $0, according to the filing.
  • Expiration date: November 9, 2036.
  • Vesting schedule: Equal monthly installments over three years, commencing December 9, 2026, and fully vested on November 9, 2029.
  • Beneficial ownership following transaction: 66,700 derivative securities, held directly.

Grant C. Bogle's Stock Option Award at Immuneering Corp

According to the Form 4 filed with the SEC on November 9, 2026, Grant C. Bogle, a Director of Immuneering Corp, acquired stock options to purchase 66,700 shares of Class A Common Stock. The exercise price of the derivative security is $3.65, and the filing records the price of the derivative security itself as $0. The options are set to expire on November 9, 2036, giving them a ten-year term from the grant date.

The filing discloses that the options vest and become exercisable "in equal monthly installments over a three year period commencing on December 9, 2026, and will be fully vested and exercisable on November 9, 2029." Following this transaction, Bogle's total beneficial ownership of this derivative security stands at 66,700 options, held directly. The Form 4 was signed by Michael D. Bookman as Attorney-in-Fact for Grant C. Bogle on November 9, 2026. No shares of non-derivative securities were reported as acquired or disposed of in this filing.

What Was Disclosed

Immuneering Corp Director Grant C. Bogle reported the acquisition of 66,700 stock options at a $3.65 exercise price, expiring November 9, 2036, with a vesting period running from December 9, 2026 through November 9, 2029, in a Form 4 dated November 9, 2026.